3Z: Zebrafish mutant model reveals novel drug candidates for ADHD

Published: Nov. 21, 2022 at 8:47 PM CST

REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the development of non-stimulant based therapeutics is of high importance. In a study published in the journal Neuropsychopharmacology, 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics. First, it was shown that when the human ADHD risk gene Latrophilin 3 was knocked-out in zebrafish, they showed a robust hyperactive behavior, consistent with ADHD. Second, it was shown that this hyperactivity can be rescued with common on-the-market ADHD therapeutics. Finally, following a large chemical screen, five novel potential therapeutics were identified. The candidates have already entered further tests. In summary, 3Z introduced a genetic model of ADHD in zebrafish and identified five novel putative therapeutics. The findings offer a novel tool for understanding ADHD, suggest a novel mechanism for its etiology and identify novel candidate therapeutics.

The study can be read here: https://www.nature.com/articles/s41386-022-01505-z

3Z´s CEO Karl Karlsson has a PhD in behavioral neuroscience and is a professor in Biomedical Engineering at Reykjavik University. Karl was extensively involved in sleep research before merging the neuroscientific and engineering skillsets to high-throughput in vivo drug screening.

Discussing the significance of the findings Karl stated:

"We are extremely pleased to publish these latest data. For us it represents a stepping stone towards developing much needed therapeutics for the market, and an important validation of our screening platform - that can be used for multiple neuropsychiatric disorders"

To find out more, please visit www.3z.is or follow on Linkedin.

CONTACT:

Karl Ægir Karlsson
karlsson@3z.is 
+3548256467

View original content:

SOURCE CISION AB

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.